Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy: a regional analysis
- Authors: Valiachmetova C.K.1, Siraev E.R.2, Izmailov A.A.2
-
Affiliations:
- Kuvatov Republican Clinical Hospital
- Republican Clinical Oncology Center
- Issue: Vol 25, No 1 (2023)
- Pages: 111-114
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132803
- DOI: https://doi.org/10.26442/18151434.2023.1.202170
- ID: 132803
Cite item
Full Text
Abstract
Background. The results of several multicenter studies indicate a high risk of severe COVID-19 and fatal outcomes in immunocompromised patients, including those with cancer. Effective prevention is critical to saving cancer patients' lives during the pandemic. Additional passive immunization with a combination of monoclonal antibodies to the SARS-CoV-2 S protein in clinical studies showed a significant reduction in the risk of severe disease and death and a decrease in the frequency of hospitalizations. Real clinical practice shows the high efficiency of this approach in patients with oncological diseases receiving immunosuppressive therapy.
Aim. To perform a comparative analysis of prevention effectiveness and COVID-19 severity in patients with solid malignant tumors receiving antitumor drug therapy.
Materials and methods. The analysis included 100 vaccinated patients aged 22 to 84 with metastatic or inoperable solid tumors who received cytostatic therapy with or without a targeted agent. The median age was 56.5 years in Group 1 and 57.7 years in Group 2. In both groups, 32 (64%) patients had breast cancer, 10 (20%) had gastric, colon, and rectal cancers, 2 (4%) had lung cancer, 4 (8%), and 6 (12%) had reproductive cancers. In addition, Group 1 included 1 patient each with bladder and brain cancer. All were treated with antitumor drug therapy following clinical guidelines according to tumor localization.
Results. The median number of received treatment lines of patients in Group 1 was 2.2, and 2.38 in Group 2. In Group 1, 42% of patients got infected, and 64% in Group 2. The combination of tixagevimab 150 mg + cilgavimab 150 mg monoclonal antibodies reduced the incidence of COVID-19 infection in any clinical form by 1.5-fold and hospitalizations by 1.3-fold. In Group 1, the rate of mild COVID-19 was higher; in Group 2, a higher risk of severe course was observed. In Group 1, viral pneumonia was 1.6-fold less common than in Group 2. Overall mortality in Group 1 was 6.5-fold lower than in Group 2. In Group 1, no COVID-19-related deaths were registered; in Group 2, the mortality rate was 8% (n=4). Mortality related to underlying disease in Group 2 was 3.5 times higher, and the risk of dying from the malignant tumor progression was 50% higher. In addition, in Group 2, 15% of deaths were related to cardiovascular diseases.
Conclusion. Adding Evusheld to vaccinated patients significantly reduces the burden of COVID-19 infection in individuals with solid neoplasms who are receiving antitumor drug therapy. Patients receiving Evusheld at any stage of the underlying disease are less likely to have COVID-19, including severe infection, which requires hospitalization in an infectious hospital. The reduction in overall mortality in the Evusheld group suggests that COVID-19 affects overall survival in cancer patients. Evusheld reduced the risk of death in cancer patients from any causes: the progression of malignant tumors, COVID-19 infection, and other comorbidities.
Full Text
##article.viewOnOriginalSite##About the authors
Chulpan K. Valiachmetova
Kuvatov Republican Clinical Hospital
Author for correspondence.
Email: chvali@bk.ru
ORCID iD: 0009-0000-7156-7280
Cand. Sci. (Med.), Kuvatov Republican Clinical Hospital
Russian Federation, UfaElsa R. Siraev
Republican Clinical Oncology Center
Email: elsas11@mail.ru
Oncilogist, Republican Clinical Oncology Center
Russian Federation, UfaAdel A. Izmailov
Republican Clinical Oncology Center
Email: izmailov75@mail.ru
ORCID iD: 0000-0002-8461-9243
D. Sci. (Med.), Republican Clinical Oncology Center
Russian Federation, UfaReferences
- Haidar G, Mellors JW. Improving the Outcomes of Immunocompromised Patients with Coronavirus Disease 2019. Clin Infect Dis. 2021;73(6):e1397-401. doi: 10.1093/cid/ciab397
- Centers for Disease Control and Prevention. Weekly updates by select demographic and geographic characteristics. Available at: https://stacks.cdc.gov/view/cdc/100078. Accessed: 08.12.2022.
- Fox L, Monroy-Iglesias MJ, Aggarwal A, et al. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England. J Cancer Policy. 2022;31:100316. doi: 10.1016/j.jcpo.2021.100316
- Gasmi A, Peana M, Pivina L, et al. Interrelations between COVID-19 and other disorders. Clin Immunol. 2021;224:108651. doi: 10.1016/j.clim.2020.108651
- Ziemba R, Campbell KN, Yang TH, et al. Excess Death Estimates in Patients with End-Stage Renal Disease – United States, February–August 2020. MMWR Morb Mortal Wkly Rep. 2021;70(22):825-9. doi: 10.15585/mmwr.mm7022e2
- Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-92. doi: 10.1182/blood.2020008824
- Fisher AM, Schlauch D, Mulloy M, et al. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Clin Transplant. 2021;35(4):e14216. doi: 10.1111/ctr.14216
- Ведение пациентов онкогематологического профиля в период пандемии COVID-19. Под ред. акад. РАН И.В. Поддубной. М.: Экон-Информ, 2022 [Vedenie pacientov onkogematologicheskogo profilya v period pandemii COVID-19. Pod red. akad. RAN IV Poddubnoj. Moscow: Ekon-Inform, 2022 (in Russian)].
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 от 14.12.2022. Режим доступа: https://edu.rosminzdrav.ru/covid-190-for-all/ Ссылка активна на 08.12.2022 [Vremennye metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya 17 ot 14.12.2022. Available at: https://edu.rosminzdrav.ru/covid-190-for-all/ Accessed: 08.12.2022 (in Russian)].
- Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 [Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost'). Pod red. AD Kaprina, VV Starinskogo, AO Shahzadovoj. Moscow: MNIOI im. PA Gercena − filial FGBU «NMIC radiologii» Minzdrava Rossii, 2022 (in Russian)].
- Поддубная И.В., Бабичева Л.Г. Вторичные иммунодефициты в онкогематологии. ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ. М.: Экон- Информ, 2019 [Poddubnaya IV, Babicheva LG. Vtorichnye immunodeficity v onkogematologii. FGBOU DPO «Rossijskaya medicinskaya akademiya nepreryvnogo professional'nogo obrazovaniya» MZ RF. Moscow: Ekon-Inform, 2019 (in Russian)].
- Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur J Cancer. 2021;159:259-74. doi: 10.1016/j.ejca.2021.10.013
- Palich R, Veyri M, Marot S, et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol. 2021;32(8):1051-3. doi: 10.1016/j.annonc.2021.04.020
- National Comprehensive Cancer Network. COVID-19 Resources. Available at: NCCN.org/covid-19. Accessed: 08.12.2022.
- Al-Obaidi MM, Gungor AB, Kurtin SE, et al. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center. Am J Med. 2023;136(1):96-9. doi: 10.1016/j.amjmed.2022.08.019
- Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386:2188-200. doi: 10.1056/NEJMoa2116620
- Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-96. doi: 10.1016/S2213-2600(22)00180-1